XB404 / Exelixis - LARVOL DELTA

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody Antibody-Drug Conjugate Candidates (GlobeNewswire) - "The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a $2.0 million milestone payment from Exelixis. XB404...is designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while minimizing on-target, off-tumor side effects. An additional payment to Adagene was triggered by the selection of candidates for another SAFEbody antibody-drug conjugate (ADC) program."

Commercial • Preclinical • Solid Tumor

Preclinical characterization of XB404, a masked anti-ROR1/2 antibody-drug conjugate (AACR 2026) - "XB404 demonstrated in vitro cytotoxicity and internalization, in vivo stability, and in vivo efficacy across multiple CDX and PDX models. Taken together, these preclinical results support further development of XB404. Investigational New Drug-enabling studies are ongoing."

ADC • Preclinical • Breast Cancer • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • ROR2

Title: Preclinical characterization of XB404, a masked anti-ROR1/2 antibody-drug conjugate (GlobeNewswire) - "...Abstract...selected for presentation at AACR 2026....Partner Exelixis will present preclinical data from antibody-drug conjugate, XB404, built with Adagene’s SAFEbody masking technology and designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while minimizing on-target, off-tumor side effects."

Preclinical • Solid Tumor

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 (Businesswire) - "Potential new development candidates:...With respect to biotherapeutics, these include XB010, the first custom ADC generated through the company’s collaboration network, which was designated a development candidate in late 2021 and will enter preclinical development shortly....Additional ADCs advancing through discovery target a range of tumor antigens including AMHR2, ROR1/2, TF and DLL3 and utilize a variety of conjugation technologies and payloads. In addition, Exelixis is advancing two bispecific programs through its Invenra collaboration that combine a PD-L1 targeting arm with either a CD47 targeting arm to block a macrophage checkpoint, or an NKG2A targeting arm to promote NK cell activation in the tumor microenvironment."

Pipeline update • Oncology